Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.

de Vries RD, Altenburg AF, Nieuwkoop NJ, de Bruin E, van Trierum SE, Pronk MR, Lamers MM, Richard M, Nieuwenhuijse DF, Koopmans MPG, Kreijtz JHCM, Fouchier RAM, Osterhaus ADME, Sutter G, Rimmelzwaan GF.

J Infect Dis. 2018 Jul 13;218(4):614-623. doi: 10.1093/infdis/jiy214.

2.

Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.

Altenburg AF, van Trierum SE, de Bruin E, de Meulder D, van de Sandt CE, van der Klis FRM, Fouchier RAM, Koopmans MPG, Rimmelzwaan GF, de Vries RD.

Sci Rep. 2018 Apr 24;8(1):6474. doi: 10.1038/s41598-018-24820-2.

3.

Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HLM, van Run PRWA, Fouchier RAM, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF.

J Virol. 2016 Oct 28;90(22):10209-10219. doi: 10.1128/JVI.01633-16. Print 2016 Nov 15.

4.

A central role for Notch in effector CD8(+) T cell differentiation.

Backer RA, Helbig C, Gentek R, Kent A, Laidlaw BJ, Dominguez CX, de Souza YS, van Trierum SE, van Beek R, Rimmelzwaan GF, ten Brinke A, Willemsen AM, van Kampen AH, Kaech SM, Blander JM, van Gisbergen K, Amsen D.

Nat Immunol. 2014 Dec;15(12):1143-51. doi: 10.1038/ni.3027. Epub 2014 Oct 26.

5.

Assessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitro.

Hillaire ML, van Eijk M, van Trierum SE, van Riel D, Saelens X, Romijn RA, Hemrika W, Fouchier RA, Kuiken T, Osterhaus AD, Haagsman HP, Rimmelzwaan GF.

PLoS One. 2011;6(9):e25005. doi: 10.1371/journal.pone.0025005. Epub 2011 Sep 14.

6.

Characterization of the human CD8⁺ T cell response following infection with 2009 pandemic influenza H1N1 virus.

Hillaire ML, van Trierum SE, Bodewes R, van Baalen CA, van Binnendijk RS, Koopmans MP, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2011 Nov;85(22):12057-61. doi: 10.1128/JVI.05204-11. Epub 2011 Sep 14.

7.

Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells.

Hillaire ML, van Trierum SE, Kreijtz JH, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF.

J Gen Virol. 2011 Oct;92(Pt 10):2339-49. doi: 10.1099/vir.0.033076-0. Epub 2011 Jun 8.

PMID:
21653752
8.

Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets.

Bodewes R, Kreijtz JH, Geelhoed-Mieras MM, van Amerongen G, Verburgh RJ, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2011 Mar;85(6):2695-702. doi: 10.1128/JVI.02371-10. Epub 2011 Jan 12.

9.

Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.

Kreijtz JH, Süzer Y, Bodewes R, Schwantes A, van Amerongen G, Verburgh RJ, de Mutsert G, van den Brand J, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Sutter G, Rimmelzwaan GF.

J Gen Virol. 2010 Nov;91(Pt 11):2745-52. doi: 10.1099/vir.0.024885-0. Epub 2010 Aug 18.

PMID:
20719991

Supplemental Content

Loading ...
Support Center